Taking Stock Of Stocks

Aiming to be Asia's No. 1 skin-health firm

In this monthly series, The Sunday Times and Singapore Exchange's research team interview company bosses to help investors get a better look at a firm's operations, one that goes beyond the financials. We speak to Hyphens Pharma chief operating officer Yann Marche.

New: Gift this subscriber-only story to your friends and family

A Our principal business, the most important one, is the speciality pharmaceuticals segment. Today, our strategy is to preserve and consolidate our existing partnership with our principal brands.

For example, Guerbet is a French pharma company specialising in contrast agents used in medical imaging. We have been partnering this firm for more than 25 years.

Already a subscriber? 

Read the full story and more at $9.90/month

Get exclusive reports and insights with more than 500 subscriber-only articles every month

Unlock these benefits

  • All subscriber-only content on ST app and straitstimes.com

  • Easy access any time via ST app on 1 mobile device

  • E-paper with 2-week archive so you won't miss out on content that matters to you

Follow ST on LinkedIn and stay updated on the latest career news, insights and more.

A version of this article appeared in the print edition of The Sunday Times on December 08, 2019, with the headline Aiming to be Asia's No. 1 skin-health firm. Subscribe